BridgeBio Pharma, Inc. Q3 FY2026 earnings call

• Atruby Commercial Momentum: The company is annualizing over $1 billion in U.S. market revenue for the Atruby/Biontra franchise. Atruby holds second place in new patient starts and is overwhelmingly leading in the first-line setting. Real-world evidence (Komodo claims data and Epic Cosmos EHR analysis) demonstrates acramidus significantly reduces clinical worsening, hospitalizations, and diuretic intensification compared to tefamidus.
• Pipeline Regulatory Updates:
  • BBP418 (LGMD2I): PDUFA date set for November 27, 2026. Expected to be the first therapy for Limb Girdle Muscular Dystrophy Type 2I. Data shows cardiac benefits, including normalization of troponin levels.
  • Infragratinib (Achondroplasia): FDA granted Priority Review with a PDUFA date of February 4, 2027. Submitted MAA to EMA for potential EU approval in H2 2027.
  • Encallerate (ADH1): NDA under Priority Review with a PDUFA date of May 8, 2027. Submitted MAA to EMA for potential EU approval in H2 2027.
• Chronic Hypoparathyroidism Expansion: First patient dosed in the Phase 3 'Reclaim HP' trial for chronic hypoparathyroidism, expanding the addressable market beyond ADH1 to ~200,000 patients in the US/EU.
• Next-Gen Therapy Nomination: BBP717, a next-generation monoclonal antibody depleter for ATTR cardiomyopathy, was nominated as a development candidate with an IND planned for 2027.
• Commercial Infrastructure: Preparedness for three imminent launches is high, with field teams deployed and patient identification programs active (e.g., identifying >500 LGMD2I patients and >600 ADH1 patients).

Total revenues for Q3 2026 were $353.2 million, a significant increase from $120.7 million in the same period of 2025. This growth was driven by Atruby (acramidus) net product revenue of $253.2 million (up ~14% sequentially and ~134% year-over-year), royalty revenue of $20.5 million, and a one-time $75 million license milestone from Bayer for Biontra (tefamidus). Atruby remains the dominant revenue contributor, representing approximately 72% of total quarterly revenue.

• Operating Expenses: Management anticipates OpEx will catch up in Q4 2026 due to timing of expenses related to the three upcoming launches, followed by modest steady growth.
• Profitability Trajectory: Confident in averaging an operating loss of around $92 million per quarter for the remainder of 2026, a significant improvement from ~$130 million per quarter in 2025.
• Long-term Outlook: Expects continued margin expansion for Atruby and an improving operating line throughout 2027, aiming for standalone profitability for all four brands by 2028.

• Regulatory/Competitive Tactics: Addressed a Citizen Petition against Infragratinib regarding neurocognitive safety concerns; management asserts this reflects competitor concern and does not impact review timelines or labels.
• Payer Restrictions: Acknowledges that UnitedHealthcare has preferred Vindamax (a silencer) over stabilizers in mid-2025, but notes Atruby continues to grow through appeals (>90% approval rate) and physician preference.
• European Regulatory Differences: For BBP418, EU authorities require full 36-month data for submission, delaying the European MAA filing to H1 2028 compared to the US launch.

Q: Analyst asked about Atruby's sequential growth sustainability and what drivers are needed to step up revenue beyond the current base. / A: CFO stated that $25-$30 million sequential increases are the right near-term base, with higher growth expected eventually. CCO emphasized focus on the first-line setting where most growth is occurring, supported by real-world evidence driving share gains in Q4 and beyond.

Q: Analyst asked about the impact of the proposed ASP change on Atruby resales and new accounts. / A: CCO clarified that the proposed ASP change impacts Part B drugs, not Part D drugs like Atruby, so there is no negative impact. He noted it could potentially level the playing field positively, but final legislation details are pending.

Q: Analyst asked about capital allocation priorities, specifically regarding acquiring Gondola or other products to improve sales force efficiency. / A: CBO stated BridgeBio is focused on executing its broad opportunity with Atruby and using AI/modern commercial tools rather than immediate M&A. Capital allocation prioritizes operations first, then retaining cash for optionality, with shareholder returns being a key consideration for excess capital.

Q: Analyst asked about the Ascendant Citizens Petition against Infragratinib and its commercial implications. / A: Franchise leader dismissed the petition as a misuse of the process by competitors, asserting it will not impact the review timeline or label. He highlighted that long-term safety data shows no CNS effects, and clinicians do not view this as a barrier to adoption.

Q: Analyst asked about the sizing of the chronic hypoparathyroidism market relative to ADH1 and the efficacy bar for the Reclaim HP study. / A: Program leader estimated ~200,000 chronic hypoparathyroidism patients vs. ~25,000 ADH1 patients. The primary endpoint is concomitant blood and urine calcium normalization. Early data suggests strongest demand from patients with persistent hypercalciuria, low bone density, or needle aversion.